ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · IEX Real-Time Price · USD
0.835
-0.009 (-1.10%)
At close: Jul 19, 2024, 4:00 PM
0.820
-0.015 (-1.80%)
Pre-market: Jul 22, 2024, 7:20 AM EDT
ImmunoPrecise Antibodies Revenue
ImmunoPrecise Antibodies had revenue of $17.67M in the twelve months ending January 31, 2024, with 16.75% growth year-over-year. Revenue in the quarter ending January 31, 2024 was $4.64M with 20.31% year-over-year growth. In the fiscal year ending April 30, 2023, ImmunoPrecise Antibodies had annual revenue of $15.42M with 0.35% growth.
Revenue (ttm)
$17.67M
Revenue Growth
+16.75%
P/S Ratio
1.24
Revenue / Employee
$173,251
Employees
102
Market Cap
21.97M USD
Revenue Chart
* The company reports in CAD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Apr 30, 2023 | 15.42M | 53.39K | 0.35% |
Apr 30, 2022 | 15.37M | 805.65K | 5.53% |
Apr 30, 2021 | 14.56M | 4.59M | 46.06% |
Apr 30, 2020 | 9.97M | 1.85M | 22.73% |
Apr 30, 2019 | 8.12M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIPA News
- 5 days ago - ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures - Business Wire
- 6 days ago - IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024 - Business Wire
- 24 days ago - ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer - Business Wire
- 27 days ago - IPA's Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™ - Business Wire
- 5 weeks ago - ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology - Business Wire
- 6 weeks ago - BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery - Business Wire
- 6 weeks ago - IPA's Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR) - Business Wire
- 3 months ago - Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results - Accesswire